Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells.
Ma S, Henson ES, Chen Y, Gibson SB. · 2016
Read Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. by Ma S, Henson ES, Chen Y, Gibson SB. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4973350.txt.
Introduction
S. Ma, E. S. Henson, Y. Chen, and S. B. Gibson show that two drugs together kill breast cancer cells by ferroptosis. Their study appeared in Cell Death and Disease in 2016. Ferroptosis is an iron dependent form of cell death driven by oxidative damage, distinct from apoptosis. The team treated four breast cancer cell lines with siramesine, a lysosome disrupting agent, and lapatinib, a kinase inhibitor. Alone each drug was modest; together they killed strongly within a day and raised reactive oxygen species.
An iron chelator drug cut both the oxidative surge and the death, which points to iron at the core. A known ferroptosis blocker also saved the cells. Treated cells took up more iron, since the iron importer transferrin rose after treatment. Removing transferrin protected the cells. The authors propose the pair as a way to force a death route that resistant breast cancers cannot easily dodge.
Catalog record
| CREATOR | Ma S, Henson ES, Chen Y, Gibson SB. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells By S Ma, E S Henson, Y Chen, S B Gibson Published in: Cell Death & Disease DOI: 10.1038/cddis.2016.208 ABSTRACT Ferroptosis is an iron-dependent, oxidative cell death, and is distinct from apoptosis, necrosis and autophagy. In this study, we demonstrated that lysosome disrupting agent, siramesine and a tyrosine kinase inhibitor, lapatinib synergistically induced cell death and reactive oxygen species (ROS) in MDA MB 231, MCF-7, ZR-75 and SKBr3 breast cancer cells over a 24 h time course. Furthermore, the iron chelator deferoxamine (DFO) significantly reduced cytosolic ROS and cell death following treatment with siramesine and lapatinib. Furthermore, we determined that FeCl3 levels were elevated in cells treated with siramesine and lapatinib indicating an iron-dependent cell death, ferroptosis. To confirm this, we treated cells with a potent inhibitor of ferroptosis, ferrastatin-1 that effectively inhibited cell death following siramesine and lapatinib treatment. The increase levels of iron could be due to changes in iron transport. We found that the expression of transferrin, which is responsible for the transport of iron into cells, is increased following treatment with lapatinib alone or in combination with siramesine. Knocking down of transferrin resulted in decreased cell death and ROS after treatment. In addition, ferroportin-1 (FPN) is an iron transport protein, responsible for removal of iron from cells. We found its expression is decreased after treatment with siramesine alone or in combination with lapatinib. Overexpression FPN resulted in decreased ROS and cell death whereas knockdown of FPN increased cell death after siramesine and lapatinib treatment. This indicates a novel induction of ferroptosis through altered iron regulation by treating breast cancer cells with a lysosome disruptor and a tyrosine kinase inhibitor. Ferroptotic cell death is a type of cell death that is morphologically, biochemically and genetically distinct from apoptosis, various forms of necrosis, and autophagy.1, 2 This process is characterized by iron-dependent accumulation of reactive oxygen species (ROS). Unlike other forms of apoptotic and non-apoptotic death,3, 4 this requirement for ROS accumulation appears to be universal. Several genes or proteins responsible for the regulation of iron and ROS metabolism have been implicated in ferroptosis, but the mechanisms to induce and regulate ferroptosis in breast cancer cells remains largely unknown. Lysosomotropic agents are drugs that destabilize the lysosome membrane directly causing leakage of lysosomal content within the cell.5 Siramesine is a sigma-2 receptor ligand that was a lysosomotropic agent and originally developed for treatment of depression.6 Although clinical trials failed to show significant efficacy in patients, there are no toxic side effects. In a variety of cancer cells including breast cancer cells, siramesine was shown to induce cell death. It was further shown to induce a rapid rise in the lysosomal pH followed by lysosomal leakage mediated in part by inhibiting sphingomyelinase (ASM). This destabilizing of lysosome membranes led to cathepsin B release and increased ROS causing cell death. Siramesine-induced cell death was independent of the activation of known caspase cascades since siramesine failed to induce detectable caspase activation and the pharmacologic caspase inhibitor z-VAD-fmk could not block the cell death.7 Lapatinib is a dual tyrosine kinase inhibitor of ErbB1 and ErbB2 tyrosine kinase receptors. Lapatinib has been approved for treatment of ErbB2-positive breast cancer and for other cancers that overexpress ErbB2. In particular, it was adopted as a therapeutic agent for the treatment of patients with ErbB2-positive refractory advanced or metastatic breast cancer, who had received previous failed treatments such as trastuzumab, anthracyclines and taxanes.8, 9 In vitro and in vivo studies demonstrated that lapatinib was able to inhibit proliferation of ErbB2 and epidermal growth factor receptor-overexpressing cancer cells and induce apoptosis.8, 9, 10 Although lapatinib provides a new treatment option for ErbB2-positive cancer, lapatinib monotherapy frequently demonstrated only modest activity in intermediate ErbB2-positive breast cancer cells.11 In this study, we investigated the synergic effects of siramesine and lapatinib on cell death in breast cancer cell lines, and the role of iron regulatory proteins and ROS in regulating ferroptosis in breasts cancer cells. RESULTS Siramesine and lapatinib-induced synergistic cell death To determine whether lysosomotropic agents are cytotoxic to breast cancer cells alone or in combination with chemotherapeutic agents, MDA MB-231 cells (triple negative breast cancer cell line) were treated with siramesine, cytotoxic agents (etoposide, cisplatin and taxol), anti-estrogen therapy (tamoxifan), and targeted chemotherapy, lapatinib (tyrosine kinase inhibitor against ErbB1/2), respectively. We found that the combination of siramesine (10 μM) and lapatinib (0.5 μM) gave a synergistic cell death response, whereas the combination of etoposide and siramesine gave an additive increase in cell death (Supplementary Figure 1). To confirm these results, we repeated these experiments in breast cancer cell lines MCF-7 and ZR-75-1 (estrogen receptor positive), and SKBr3 cells (estrogen receptor negative, ErbB2 over expressed) as these cell lines represent different subtypes of breast cancer. We found that the combination of siramesine and lapatinib-induced cell death to a great extent than the treatments alone, 10 versus 40% cell death (Figure 1a). The MDA MB 231 and SKBr3 cell lines were then treated over a 24 h time course and the amount of cell death determined. The combination of siramesine (10 μM) and lapatinib (0.5 μM) increased cell death in a time dependent manner with 35–45% cell death after 24 h. Treatment with DMSO, siramesine or lapatinib alone failed to induce cell death over this 24 h time course (Figures 1b and c). The MDA MB 231 and SkBr3 cell lines were also treated over a dose range of siramesine or lapatinib showing increased cell death in dose dependent manner (Supplementary Figure 2). Furthermore, using a cell viability assay (MTT assay), we showed decreased cell survival when siramesine and lapatinib were combined (Figure 1d). We also determine the extent of synergistic cell death using isobolograms. We found the combination index (CI) to be <1 for the combination of siramesine and lapatinib in both MDA MB 231 and SKBr3 cell lines indicating synergy (Supplementary Figure 3). We also determine whether this combination induces synergistic cell death in non-malignant cell lines. We treated the epithelial mammary cell line (MCF-10A1) with siramesine and lapatinib. We found the drug combination failed to significantly increased cell death compared to breast cancer cell lines (Supplementary Figure 5). These results suggest that siramesine and lapatinib-induced synergic cell death in breast cancer cells. Ferroptosis is induced by siramesine and lapatinib treatment Lapatinib has been shown to induce apoptosis at high concentrations.12, 13, 14 We next determined whether combination of siramesine and lapatinib treatment-induced apoptosis. Treated cells were evaluated for apoptosis by using subG1 and Annexin V staining assays. We failed to observe significant apoptotic cell death after 4 h (Supplementary Figures 6A and B). To support this finding, we treated cells with caspase inhibitor z-VAD-fmk and determine the amount of total cell death. The caspase inhibitor failed to block siramesine and lapatinib-induced cell death (Supplementary Figure 6C) whereas z-VAD-fmk was effective at reducing cisplatin-induced cell death. (Supplementary Figure 6D).The caspase 3 activity was also unchanged after siramesine and lapatinib treatment (Supplementary Figure 6D). In addition, both PARP and caspase 3 failed to be cleaved following combined treatment with siramesine and lapatinib (Supplementary Figure 6E). These results suggest that the combination of siramesine and lapatinib is not